EXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type 2 diabetes medications'
Portfolio Pulse from Benzinga Newsdesk
Vivani Medical is studying NPM-119 to address medication non-adherence and improve tolerability issues associated with oral and injectable type 2 diabetes medications.
June 13, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivani Medical is developing NPM-119 to address medication non-adherence and improve tolerability for type 2 diabetes treatments.
The development of NPM-119 by Vivani Medical could lead to better treatment adherence and tolerability for type 2 diabetes patients, potentially increasing the company's market share and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100